Literature DB >> 15364452

Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.

Marien I de Jonge1, Hendrik Jan Hamstra, Wim Jiskoot, Paul Roholl, Neil A Williams, Jacob Dankert, Loek van Alphen, Peter van der Ley.   

Abstract

The opacity (Opa) proteins of Neisseria meningitidis are outer membrane proteins involved in adhesion and invasion of host epithelial cells and are therefore expected to play an important role in colonisation of the nasopharynx. The majority of meningococcal Opa proteins bind to members of the CEACAM receptor family, such as CEA. Blocking of the Opa-CEACAM interaction by mucosal anti-Opa antibodies could thus constitute an important protective mechanism for novel meningococcal vaccines. In this study we analysed the specific anti-Opa antibody responses after intranasal immunisation of mice with liposomes containing purified and native OpaB (recognising the CEA receptor) and OpaJ (no affinity for CEA) proteins. These antigens were combined with or without one of three different adjuvants, i.e. purified meningococcal LPS, monophosphoryl lipid A (MPL) or the B-subunit of Escherichia coli heat-labile enterotoxin (EtxB). After intranasal immunisation with any of these formulations, anti-Opa IgA antibodies were found in nasal lavages and in some cases anti-Opa IgA and IgG antibodies were also found in lung lavages. With OpaJ but not OpaB, significant bactericidal serum titres were obtained. Of the different adjuvants used, meningococcal LPS gave the strongest overall immune response. Non-adjuvated liposomal Opa formulations were poorly immunogenic. No differences were found between the immune response in transgenic mice expressing the CEA-receptor and non-transgenic mice, showing that the CEA-Opa interaction does not influence the antibody response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364452     DOI: 10.1016/j.vaccine.2004.03.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Current prospects and future challenges for nasal vaccine delivery.

Authors:  Helmy Yusuf; Vicky Kett
Journal:  Hum Vaccin Immunother       Date:  2016-12-09       Impact factor: 3.452

2.  Vaccines against gonorrhea: current status and future challenges.

Authors:  Ann E Jerse; Margaret C Bash; Michael W Russell
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

3.  A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.

Authors:  William M Gwinn; Brandi T Johnson; Shaun M Kirwan; Ashley E Sobel; Soman N Abraham; Michael D Gunn; Herman F Staats
Journal:  Vaccine       Date:  2013-01-23       Impact factor: 3.641

4.  Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Authors:  Jesús Arenas; Harry van Dijken; Betsy Kuipers; Hendrik Jan Hamstra; Jan Tommassen; Peter van der Ley
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

5.  Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis.

Authors:  Fabiana R Santos; Denise B Ferraz; Katia R P Daghastanli; F Juarez Ramalho-Pinto; Pietro Ciancaglini
Journal:  J Membr Biol       Date:  2006-08-14       Impact factor: 2.426

Review 6.  Mucosal Vaccine Development Based on Liposome Technology.

Authors:  Valentina Bernasconi; Karin Norling; Marta Bally; Fredrik Höök; Nils Y Lycke
Journal:  J Immunol Res       Date:  2016-12-29       Impact factor: 4.818

7.  Functional characterization of antibodies against Neisseria gonorrhoeae opacity protein loops.

Authors:  Jessica G Cole; Ann E Jerse
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

8.  Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.

Authors:  Manish Sadarangani; J Claire Hoe; Martin J Callaghan; Claire Jones; Hannah Chan; Katherine Makepeace; Hélène Daniels-Treffandier; Mary E Deadman; Christopher Bayliss; Ian Feavers; Peter van der Ley; Andrew J Pollard
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

9.  Positively selected codons in immune-exposed loops of the vaccine candidate OMP-P1 of Haemophilus influenzae.

Authors:  Ted H M Mes; Jos P M van Putten
Journal:  J Mol Evol       Date:  2007-03-19       Impact factor: 2.395

Review 10.  Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.

Authors:  Jennifer L Edwards; Michael P Jennings; Michael A Apicella; Kate L Seib
Journal:  Crit Rev Microbiol       Date:  2016-01-23       Impact factor: 7.624

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.